The Future of Remote Musculoskeletal Care

Remote therapeutic monitoring (RTM) started its life as a payment vehicle. Codes that paid for clinician time spent reviewing patient device data outside a visit. Three years on, RTM has matured into something more interesting. It is becoming the operational backbone of how musculoskeletal pain programs run, because the workflow that the codes were designed to compensate is the workflow that actually works for chronic pain care.

What RTM actually buys you

RTM, used well, buys you continuity. A patient leaves the clinic with a device. The device captures usage. The patient adds brief structured check ins. The clinician reviews the stream periodically and adjusts. The relationship does not pause between visits. For chronic pain, where outcomes hinge on adherence and dosing more than on the brilliance of any single decision in the office, that continuity is the meaningful upgrade. Pain is not solved by the visit. Pain is managed in the weeks between visits, and RTM funds the structure that makes that management visible.

Why the bioelectric category fits cleanly

A bioelectric wearable is the right kind of device for an RTM workflow because it produces structured, continuous, low burden data. Use time. Intensity. Body region. Patient reported pain. The dataset is small per patient and large per population. It is exactly the dataset the codes assume. The Electrome platform's data layer is purpose built to produce that dataset without imposing manual logging on the patient or the clinician.

What providers actually do

In a real provider workflow, the clinician opens the workspace once a week or once every few weeks. The platform highlights the patients whose adherence has slipped, whose pain trends have changed, whose check ins flag something that warrants a touch. The clinician spends the review time on those patients. The patients whose stream is going as expected do not need a touch. That triage is the core of how a small clinical team can scale chronic pain care without burning out.

The cross channel piece

The interesting wrinkle, and the part most clinicians are not yet used to, is that the patient may have entered the program through a non clinical channel. A retail purchase. An affiliate referral. A direct to consumer onboarding. In a coordinated platform, that patient can be transferred into a clinical relationship at the moment a clinical relationship makes sense, without losing the data backbone that has already accumulated. That cross channel continuity is the part that platforms uniquely deliver.

What this changes for partners

For retail partners, the implication is that selling a bioelectric device is the start of a relationship, not the end of one. The patient who buys the device can be enrolled into a program that supports their use, and that support raises both clinical outcomes and customer lifetime value. For affiliate creators, the implication is similar. The relationship with the audience extends past the transaction because the platform supports the audience after the purchase.

What this changes for the system

For the larger system, the implication is that musculoskeletal pain care can be delivered with a different cost structure than it has been. Less clinic time per patient. More continuity per patient. Better documented outcomes. The category that figures out how to operationalize this at scale is the category that gets to define what musculoskeletal pain care looks like for the next decade. The bioelectric category is one of the candidates, and the Electrome platform is one of the bets inside that category.